Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07554755

TIS for NSSI in Adolescent Depression

Temporal Interference Stimulation (TIS) has been successfully used to help patients with depression. However, its role in alleviating self injuries remained uncertain. This trial will compare the effectiveness of TIS to a placebo control on non-suicidal self injury (NSSI) in patients with major depressive disorder(MDD).

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 year–22 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The study will evaluate the efficacy and safety of TIS in depressive patients with NSSI behaviors by measuring changes in clinical ratings at baseline, after all the treatments, and 2 weeks, 4 weeks, 8 weeks after treatment. 60 inpatients will be randomized to receive active or sham interventions administered to the right subgenual anterior cingulate cortex. The treatment will apply TIS involving 2x daily at 30 minutes for 5-7 days.

Changes in mood from baseline to the end of the study will be measured with The Hamilton Rating Scale for Depression-17 item (HAMD-17), Hamilton Anxiety Scale (HAMA). Non-suicidal self injury will be assessed by the Adolescent Non-Suicidal Self-Injury Assessment Questionnaire (ANSAQ). Suicidal ideation and behaviors assessments will be measured with Beck Suicidal Scale Inventory (BSI). Changes in somatic symptom severity from baseline to the end of the study will be measured with the Patient Health Questionnaire-15 (PHQ-15). Sleep quality and disturbances will be assessed by the Pittsburgh Sleep Quality Index (PSQI). Insomnia severity will be evaluated using the Insomnia Severity Index (ISI). Ruminative thinking styles will be measured with the Ruminative Responses Scale (RRS). Impulsivity and aggression assessments will be measured with the Barratt Impulsiveness Scale (BIS) and the Buss-Perry Aggression Questionnaire (BPAQ), respectively. Additionally, pain-related attention and hypervigilance will be assessed by the Pain Vigilance and Awareness Questionnaire (PVAQ). Adverse event record form (AERF) will be used to appraise the safety of TIS treatment. Changes of brain structure and brain activities will be acquired by pre and post-interventional magnetic resonance imaging (MRI).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) diagnostic criteria for major depressive disorder.
  • Patients aged 12-22 years with at least one guardian to monitor them for 3 months
  • HAMD-17 Total score ≥18
  • Patients who had two or more non-suicidal self-injury behaviors meeting the 5.DSM-5 diagnostic criteria in the 2 weeks before admission (NSSI behavior of more than 5 days in the past year)

6.Obtain informed consent from patients and guardians

-

Exclusion criteria

  • Substance abusers such as psychoactive drugs or alcohol.
  • Severe physical disability and unable to complete follow-up.
  • Comorbid other major mental illnesses that meet the DSM-5 criteria, such as bipolar disorder, schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc.
  • Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime.

Unable to read, understand and complete the assessment or to cooperate with the investigators.

  • Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for TIS.
  • Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) or TMS within 3 months before baseline.
  • Other examination abnormalities considered to be inappropriate by investigators.

-

Treatment and study plan

Active Temporal Interference Stimulation (TIS)

Device

Active stimulation to the right subgenual anterior cingulate cortex; 2 sessions per day, 30 minutes per session, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end, for 5-7 days.

Sham Temporal Interference Stimulation (TIS)

Device

Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation.

Primary outcomes

  1. Changes in the Adolescent Non-Suicidal Self-Injurious Behavior Assessment Questionnaire (ANSAQ)

    Time frame: Baseline, the day after the end of TIS, 2 weeks after the end of TIS, 4 weeks after the end of TIS, 8 weeks after the end of TIS

    Containing one subscale evaluating the frequency and primary methods of self-injury behaviors in patients over the past 2 weeks,and one subscale ranging from 0 to 10 to assess the self-injurious thoughts, with 0 indicating "not at all" and 10 indicating "very strongly."

  2. Changes in the 17-item Hamilton Rating Scale for Depression (HAMD-17)

    Time frame: Baseline, the day after the end of TIS, 2 weeks after the end of TIS, 4 weeks after the end of TIS, 8 weeks after the end of TIS

    Range from 0-52, higher score indicates more severe symptoms

Secondary outcomes

  1. Changes in Hamilton Anxiety Scale (HAMA)

    Time frame: Baseline, the day after the end of TIS, 2 weeks after the end of TIS, 4 weeks after the end of TIS, 8 weeks after the end of TIS

    Range from 0-56, higher score indicates more severe symptoms

  2. Change in the Patient Health Questionnaire-15 (PHQ-15)

    Time frame: Baseline, the day after the end of TIS, 2 weeks after the end of TIS, 4 weeks after the end of TIS, 8 weeks after the end of TIS

    Range from 0 to 30, higher score indicates more severe somatic symptoms.

  3. Changes in Insomnia Severity Index (ISI)

    Time frame: Baseline, the day after the end of TIS, 2 weeks after the end of TIS, 4 weeks after the end of TIS, 8 weeks after the end of TIS

    Range from 0 to 28. Higher scores indicate more severe insomnia symptoms.

  4. Changes in Ruminative Responses Scale (RRS)

    Time frame: Baseline, the day after the end of TIS

    Range from 22 to 88. Higher scores indicate higher levels of ruminative thinking.

  5. Changes in Beck Suicidal Scale Inventory (BSI)

    Time frame: Baseline, the day after the end of TIS

    Range from 0- 38, higher score indicates more severe suicide ideation.

  6. Chinese version of the Barratt Impulsiveness Scale

    Time frame: Baseline, the day after the end of TIS

    Total score ranges from 0 to 100. It is converted from a 30-item raw score based on a 5-point scale. Higher scores indicate greater levels of impulsivity.

  7. Changes in the Chinese version of the Buss & Perry Aggression Questionnaire

    Time frame: Baseline, the day after the end of TIS

    Total score ranges from 0 to 100. It is mathematically converted from the sum of the raw item scores. Higher scores indicate greater levels of aggression.

  8. Changes in Pain Vigilance and Awareness Questionnaire (PVAQ)

    Time frame: Baseline, the day after the end of TIS

    Range from 0 to 80. Higher scores indicate greater pain-related attention and hypervigilance.

  9. Changes of high-resolution T1-weighted anatomical images

    Time frame: Baseline, the day after the end of TIS

    T1-weighted images will be acquired using 3D inversion recovery-prepared fast spoiled gradient-echo sequences.

  10. Changes of blood oxygenation level dependent (BOLD) functional imaging signals

    Time frame: Baseline, the day after the end of TIS

    Resting-state MRI (rs-MRI) will be used to exam the change of brain function.

  11. Changes of Diffusion Tensor Imaging

    Time frame: Baseline, the day after the end of TIS

    Diffusion Tensor Imaging (DTI) will be performed using diffusion-weighted echo planar imaging sequences.

Other outcomes

  1. Changes in the Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Baseline

    Total score ranges from 0 to 21. Higher scores indicate poorer overall sleep quality and more severe sleep disturbances.

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Time frame: The day after the end of TIS

    Recording any side effects in the adverse event record form (AERF).

Study contacts

Contact information is provided by the study sponsor or research team.

Hongping Wang

CONTACT

[email protected]

+86-18256001073

Yanghua Tian, PhD

CONTACT

[email protected]

+86-13955188448

Sponsors and collaborators

Lead sponsor

The Second Hospital of Anhui Medical University

Other

Registry information

Official study title

Efficacy and Safety of Temporal Interference Stimulation on Non-suicidal Self-injury Behaviors in Adolescents With Depression

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Apr 28, 2026
Registry last updated
Apr 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.